Ahmed Nisar, Kumari Ayushi, Murty R Srinivasa
Aditya Pharmacy Collage, Surampalem, Andhra Pradesh, India.
Jawaharlal Nehru Technological University, Kakinada, India.
J Ultrasound. 2024 Nov 19. doi: 10.1007/s40477-024-00971-z.
FibroScan, initially designed for assessing cheese maturity, has evolved into a crucial medical tool for liver fibrosis diagnosis. This systematic review explores its development history, functionality, and pros and cons compared to traditional liver biopsy. Precision in various clinical settings is scrutinised, emphasising FibroScan's accuracy in conditions like NAFLD and viral-induced liver disease. The article also delves into its potential in paediatrics, its relevance in monitoring COVID-19-related liver complications, and its role in predicting hepatocellular carcinoma risk, Technical aspects, including transducers, imaging integration, and portability, are examined. Various methods for evaluating liver fibrosis are discussed, highlighting FibroScan's suitability for advanced stages, contrasting with the gold standard of liver biopsy for early stages. The impact of FibroScan on long-term liver conditions is emphasised, focusing on early detection, progression monitoring, reduced invasive biopsies, and hepatocellular carcinoma risk prediction. This systematic review underscores FibroScan's transformative potential in liver disease treatment and predicts ongoing research to enhance early detection, disease monitoring, and explore new clinical applications. Anticipated advances include FibroScan-guided liver biopsy, artificial intelligence data analysis, and point-of-care device development, promising a further revolution in liver disease management. The article concludes with optimistic prospects for FibroScan's future.
FibroScan最初设计用于评估奶酪的成熟度，现已发展成为肝脏纤维化诊断的关键医学工具。本系统综述探讨了其发展历程、功能以及与传统肝活检相比的优缺点。研究了其在各种临床环境中的准确性，强调了FibroScan在非酒精性脂肪性肝病（NAFLD）和病毒感染性肝病等病症中的准确性。文章还深入探讨了其在儿科的应用潜力、在监测COVID-19相关肝脏并发症方面的相关性以及在预测肝细胞癌风险方面的作用。对包括换能器、成像整合和便携性在内的技术方面进行了研究。讨论了评估肝纤维化的各种方法，强调了FibroScan对晚期的适用性，与早期阶段肝活检的金标准形成对比。强调了FibroScan对长期肝脏疾病的影响，重点在于早期检测、病情监测、减少侵入性活检以及肝细胞癌风险预测。本系统综述强调了FibroScan在肝病治疗中的变革潜力，并预测未来将继续开展研究以加强早期检测、疾病监测并探索新的临床应用。预期进展包括FibroScan引导下的肝活检、人工智能数据分析以及即时检测设备的开发，有望在肝病管理方面带来进一步的革命。文章最后对FibroScan的未来前景持乐观态度。
